Semaglutide and tirzepatide are two of the most talked-about names in metabolic medicine, and they are often mentioned in the same breath. They share a lot — both are typically weekly injectables, both act on appetite and blood-sugar regulation, and both are available in compounded form through telehealth. But they are not the same molecule, and the difference in how they work is worth understanding before you assume one is simply a “stronger” version of the other.
The shared foundation: GLP-1
GLP-1 (glucagon-like peptide-1) is one of the body’s incretin hormones. It helps regulate blood sugar, signals fullness to the brain, and slows gastric emptying so food stays in the stomach longer. Medications in this class mimic that hormone’s activity. Semaglutide is a single-pathway GLP-1 receptor agonist — it acts on the GLP-1 receptor.
What makes tirzepatide different
Tirzepatide is a dual-action molecule. In addition to acting on the GLP-1 receptor, it also acts on a second incretin pathway, GIP (glucose-dependent insulinotropic polypeptide). That is the core distinction often summarized as “single-pathway versus dual-pathway.” Tirzepatide engages two hormone receptors involved in appetite and blood-sugar regulation, while semaglutide engages one.
How they are alike
- Both are typically administered as once-weekly subcutaneous injections.
- Both are usually started at a low dose and titrated upward gradually under provider supervision.
- Both share a similar profile of common early side effects, most often gastrointestinal — nausea, fullness, and digestive changes — especially around starting and after dose increases.
- Both are available as compounded preparations, which are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or quality.
How they tend to differ
- Mechanism: semaglutide acts on one incretin pathway (GLP-1); tirzepatide acts on two (GLP-1 and GIP).
- Titration schedules and dose units differ between the two medications, so the numbers are not directly comparable.
- Cost ranges can differ; specifics depend on the product, dose, and provider.
Why the units are not directly comparable
A common source of confusion is comparing the milligram numbers on each medication as if they measure the same thing. They do not. Semaglutide and tirzepatide are different molecules with different dosing scales and different titration schedules, so a given milligram figure on one says nothing about the equivalent on the other. Reading the dose of one as “stronger” because the number is higher or lower is a mistake — the meaningful comparison is how a person responds under provider supervision, not the printed figure.
Why the choice is a provider’s decision
It is tempting to treat this as a head-to-head where one wins. In practice, the decision depends on factors a clinician is trained to weigh: your medical history, other medications, how you tolerate a given molecule, your goals, and your response over time. A licensed provider — not an algorithm and not the patient — selects the molecule, the starting dose, and the titration plan, and only if treatment is determined to be appropriate. The provider may also adjust course if the first choice is not the right fit, or recommend neither if treatment is not suitable for you.
It also bears repeating that compounded versions of either molecule are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or quality. Compounded GLP-1 products were widely marketed online during the shortages of 2023 and 2024, but the FDA declared those shortages resolved (tirzepatide in December 2024, semaglutide in February 2025), and the shortage-based justification for compounding them no longer applies. That status is the same for both molecules; it is not a point of difference between them.
The bottom line
Semaglutide and tirzepatide are related but distinct: same broad family, different mechanisms, with tirzepatide adding a second pathway. Neither is universally “better,” and both require a licensed provider’s judgment. Availability varies by state and individual results vary. This article compares two molecules; it is not an offer of either one, and TEXPEPS does not market compounded GLP-1 products. If you want to know which, if either, might be appropriate for you, that is a conversation to have with a licensed provider.